Avertix Medical, Inc. and BIOS Acquisition Corporation have mutually agreed to terminate their proposed business combination. Avertix is a company focused on improving long-term management and outcomes of high-risk coronary disease in patients who have survived one or more heart attacks, while BIOS is a special purpose acquisition company.